Last reviewed · How we verify
Modified-Release Prednisone
At a glance
| Generic name | Modified-Release Prednisone |
|---|---|
| Also known as | Rayos |
| Sponsor | Minneapolis Veterans Affairs Medical Center |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
- Headache
- Viral Upper Respiratory Tract Infection
- Fatigue
- Rheumatoid arthritis
- Nausea
- Therapeutic Response Unexpected
- Dizziness
- Pyrexia
- Vomiting
- Malaise
- Nasopharyngitis
- Abdominal pain (upper)
Key clinical trials
- Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease (PHASE2)
- Study to Assess the Safety and Efficacy of Modified-Release Prednisone (Lodotra®) Therapy in Patients With Active Rheumatoid Arthritis (PHASE3)
- A New Modified-release Tablet Formulation of Prednisone (Lodotra®) in Patients With Nocturnal Asthma (PHASE2)
- Gulf War Illness Inflammation Reduction Trial (PHASE2)
- Open-label Comparison of Chronocort® Versus Standard Glucocorticoid Replacement Therapy (PHASE3)
- Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia (PHASE3)
- Low Dose Prednisone Therapy in Women With Recurrent Pregnancy Loss (PHASE2, PHASE3)
- A Study Assessing the Efficacy and Safety of Lodotra® Compared to Prednisone IR in Subjects Suffering From PMR (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Modified-Release Prednisone CI brief — competitive landscape report
- Modified-Release Prednisone updates RSS · CI watch RSS
- Minneapolis Veterans Affairs Medical Center portfolio CI